RecruitingPhase 1NCT03604315

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT

Sponsor

M.D. Anderson Cancer Center

Enrollment

300 participants

Start Date

Dec 18, 2018

Study Type

INTERVENTIONAL

Conditions

Breast Carcinoma Ovarian Carcinoma Primary Peritoneal Carcinoma Recurrent Ovarian Carcinoma Fallopian Tube Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Primary Peritoneal Carcinoma Solid Neoplasm

Summary

This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of PET scan tracer called FLuorthanatrace (FTT) to see how well it can detect solid tumors in people with cancer. PET scans use a small amount of radioactive material to highlight areas of the body where cancer cells are active. **You may be eligible if...** - You have a known or suspected solid tumor (such as breast, lung, or prostate cancer) - You have at least one tumor that is 1 cm or larger and visible on standard scans (CT, MRI, ultrasound, or PET) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are unable to tolerate the imaging procedure - You have a serious medical condition, illness, or disorder that your doctor believes makes participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.